ATE194493T1 - Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure - Google Patents

Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure

Info

Publication number
ATE194493T1
ATE194493T1 AT93300052T AT93300052T ATE194493T1 AT E194493 T1 ATE194493 T1 AT E194493T1 AT 93300052 T AT93300052 T AT 93300052T AT 93300052 T AT93300052 T AT 93300052T AT E194493 T1 ATE194493 T1 AT E194493T1
Authority
AT
Austria
Prior art keywords
treating
combination
rapamycin
mycophenolic acid
hyperproliferactive
Prior art date
Application number
AT93300052T
Other languages
English (en)
Inventor
Randall Ellis Morris
Clare Robert Gregory
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of ATE194493T1 publication Critical patent/ATE194493T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT93300052T 1992-01-09 1993-01-06 Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure ATE194493T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81931492A 1992-01-09 1992-01-09

Publications (1)

Publication Number Publication Date
ATE194493T1 true ATE194493T1 (de) 2000-07-15

Family

ID=25227805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93300052T ATE194493T1 (de) 1992-01-09 1993-01-06 Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure

Country Status (15)

Country Link
EP (1) EP0551182B1 (de)
JP (1) JP2644955B2 (de)
KR (1) KR100276142B1 (de)
AT (1) ATE194493T1 (de)
AU (1) AU665041B2 (de)
CA (1) CA2086642C (de)
DE (1) DE69328981T2 (de)
DK (1) DK0551182T3 (de)
ES (1) ES2147740T3 (de)
GR (1) GR3034479T3 (de)
HK (1) HK1010332A1 (de)
LV (1) LV12603B (de)
NZ (1) NZ245630A (de)
PT (1) PT551182E (de)
SG (1) SG47639A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DK1155689T3 (da) 1993-07-19 2006-11-20 Angiotech Pharm Inc Antiangiogene stents og fremgangsmåder til fremstilling heraf
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
NZ311647A (en) 1995-06-09 1999-11-29 Novartis Ag Rapamycin derivatives
KR100616020B1 (ko) * 1996-03-27 2007-01-31 노파르티스 아게 맥관장애및이종이식술에서의라파마이신유도체의용도
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) † 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6702849B1 (en) 1999-12-13 2004-03-09 Advanced Cardiovascular Systems, Inc. Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
AU2001294634B2 (en) 2000-10-16 2006-07-06 Innovational Holdings, Llc Expandable medical device for delivery of beneficial agent
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ATE538820T1 (de) 2003-02-21 2012-01-15 Sorin Biomedica Cardio Srl Verfahren zur herstellung eines stents und entsprechender stent
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7303758B2 (en) * 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
JP5141254B2 (ja) 2005-10-06 2013-02-13 株式会社カネカ 生体留置用ステント
JP2010500889A (ja) 2006-07-03 2010-01-14 ヘモテック アーゲー 恒久的に血管を開いた状態にするための薬剤溶出医療デバイスの製造、方法、および使用
BRPI0806727B8 (pt) 2007-01-21 2021-06-22 Hemoteq Ag método para o revestimento de um cateter de balão
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
WO2009089549A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
WO2011005421A2 (en) 2009-07-10 2011-01-13 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
JP6278332B2 (ja) 2013-04-22 2018-02-14 スズキ株式会社 変速機の制御装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus

Also Published As

Publication number Publication date
EP0551182A1 (de) 1993-07-14
NZ245630A (en) 1997-07-27
ES2147740T3 (es) 2000-10-01
SG47639A1 (en) 1998-04-17
KR100276142B1 (ko) 2001-02-01
JPH069390A (ja) 1994-01-18
AU3107993A (en) 1993-07-15
PT551182E (pt) 2000-12-29
KR930016102A (ko) 1993-08-26
AU665041B2 (en) 1995-12-14
LV12603B (en) 2001-04-20
EP0551182B1 (de) 2000-07-12
JP2644955B2 (ja) 1997-08-25
DE69328981D1 (de) 2000-08-17
HK1010332A1 (en) 1999-06-17
CA2086642C (en) 2004-06-15
CA2086642A1 (en) 1993-07-10
DK0551182T3 (da) 2000-10-09
GR3034479T3 (en) 2000-12-29
LV12603A (en) 2001-01-20
DE69328981T2 (de) 2000-11-16

Similar Documents

Publication Publication Date Title
ATE194493T1 (de) Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure
DE69524679T2 (de) Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
DE58905979D1 (de) Verfahren zur aufzucht von wassertieren.
ATE324866T1 (de) Verfahren zur behandlung von gefässrestenose durch inhalieren von stickoxid
DE69232565T2 (de) Verfahren zur behandlung von lungenerkrankungen mit uridin-triphosphaten
DE69010162T2 (de) Zusammensetzung zur Behandlung von Entzündung.
DE3867736D1 (de) Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels.
DE3874028D1 (de) Verfahren zur justierung von photomasken.
DE69307617T2 (de) Verwendung von Kompetitiven NMDA-Rezeptorantagonisten zur Behandlung der Harninkontinenz
ATE201388T1 (de) Verfahren zur verbesserung der biozidaktivität
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE58904328D1 (de) Verfahren zur desinfektion von medizinischen abformmassen.
ATE253728T1 (de) Pyrogen-untersuchungsverfahren
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
DE59103291D1 (de) Verfahren zur bekämpfung von samen- und/oder bodenbürtigen schaderregern durch saatgutbehandlung.
DE3886755T2 (de) Verfahren zur behandlung von gefässkrankheiten.
DE69006509D1 (de) Verfahren zur behandlung von häuten.
DE68907914T2 (de) Verfahren zur behandlung von brandwunden.
GR1002803B (el) Μεθοδος αποφυγης της κακοσμιας που αναπτυσσεται κατα την βοστρυχωση των μαλλιων με την εφαρμογη κυστεαμινης και αλλων θειουχων ενωσεων.
DE68905602D1 (de) Verfahren zur behandlung von titanstrukturen.
DE3863762D1 (de) Verfahren zur behandlung von frischholz.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification